Abbott Laboratories (ABT) FY2025 10-K Annual Report
Abbott Laboratories (ABT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 20, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Abbott Laboratories FY2025 10-K Analysis
Business Overview
- • Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
- • Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
Management Discussion & Analysis
- • Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
- • Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
Risk Factors
- • IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
- • Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
Abbott Laboratories FY2025 Key Financial MetricsXBRL
Revenue
$44.3B
▲ +5.7% YoY
Net Income
$6.5B
▼ -51.3% YoY
Operating Margin
18.2%
▲ +190bp YoY
Net Margin
14.7%
▼ -1723bp YoY
ROE
12.5%
▼ -1560bp YoY
Total Assets
$86.7B
▲ +6.5% YoY
EPS (Diluted)
$3.72
▼ -51.3% YoY
Operating Cash Flow
$9.6B
▲ +11.8% YoY
Source: XBRL data from Abbott Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Abbott Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.